INDVIndivior Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $1.2B
- 4.3% YoY
- Operating margin
- 21.1%
- 561% YoY
- EBITDA
- $272M
- 404% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.1×
- −$305M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-13% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-41% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|
| Revenue | $901M | $1.1B | $1.2B | $1.2B | 4.3% |
| Operating income | −$77M | −$152M | $38M | $262M | 589% |
| Net income | −$42M | −$126M | $7M | $210M | 2900% |
| Operating cash flow | −$4M | −$300M | $36M | −$27M | 175% |
| Capex | $5M | $8M | $29M | $66M | 128% |
| Stock-based comp | $16M | $21M | $24M | $26M | 8.3% |
| Buybacks | $90M | $33M | $173M | $11M | 94% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $30K · 1
- Open-market sells, 12 mo
- $0 · 0
- Net
- $30K
Pay vs performance
No pay-versus-performance disclosure yet.